Russell Investments Group
CHRS icon

Russell Investments Group’s Coherus Oncology CHRS Stock Holding History

Russell Investments Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Buy
14,230
+5,446
+62% +$9.67K ﹤0.01% 3567
2025
Q4 		$12.5K Hold
8,784
– – ﹤0.01% 3738
2025
Q3 		$14.4K Buy
+8,784
New +$9.77K ﹤0.01% 3699
2025
Q1 		– Sell
-743
Closed -$1.02K – 3809
2024
Q4 		$1.02K Buy
+743
New +$833 ﹤0.01% 3521
2024
Q3 		– Sell
-72,955
Closed -$126K – 3707
2024
Q2 		$126K Buy
+72,955
New +$147K ﹤0.01% 2578
2024
Q1 		– Sell
-73,102
Closed -$243K – 3315
2023
Q4 		$243K Buy
+73,102
New +$196K ﹤0.01% 2393
2023
Q3 		– Sell
-1,155
Closed -$4.93K – 3540
2023
Q2 		$4.93K Sell
1,155
-86,695
-99% -$512K ﹤0.01% 3112
2023
Q1 		$601K Sell
87,850
-2,644
-3% -$20.5K ﹤0.01% 2188
2022
Q4 		$717K Buy
90,494
+8,141
+10% +$62.6K ﹤0.01% 2138
2022
Q3 		$789K Sell
82,353
-25,689
-24% -$260K ﹤0.01% 2038
2022
Q2 		$781K Buy
108,042
+86,542
+403% +$753K ﹤0.01% 2068
2022
Q1 		$277K Buy
+21,500
New +$273K ﹤0.01% 2390
2021
Q2 		– Sell
-66,535
Closed -$971K – 3217
2021
Q1 		$971K Sell
66,535
-24,316
-27% -$413K ﹤0.01% 2256
2020
Q4 		$1.58M Buy
90,851
+25,169
+38% +$448K ﹤0.01% 1881
2020
Q3 		$1.2M Buy
65,682
+14,393
+28% +$268K ﹤0.01% 1978
2020
Q2 		$915K Sell
51,289
-10,467
-17% -$177K ﹤0.01% 2107
2020
Q1 		$1M Buy
61,756
+24,956
+68% +$461K ﹤0.01% 1839
2019
Q4 		$662K Sell
36,800
-63,204
-63% -$1.17M ﹤0.01% 2296
2019
Q3 		$2.03M Buy
+100,004
New +$2M ﹤0.01% 1679
2017
Q3 		– Sell
-5,888
Closed -$84K – 2950
2017
Q2 		$84K Sell
5,888
-19,839
-77% -$382K ﹤0.01% 2828
2017
Q1 		$545K Sell
25,727
-11,390
-31% -$280K ﹤0.01% 2391
2016
Q4 		$1.05M Buy
+37,117
New +$1.04M ﹤0.01% 2150

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Russell Investments Group's CHRS Position: Q1 2026 in Review

Russell Investments Group increased its Coherus Oncology (CHRS) stake by 62% in Q1 2026, buying an estimated $9.67K and bringing the position to 14,230 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3567.

Russell Investments Group first reported a position in CHRS in Q4 2016 and has held it in 22 quarters since. The position peaked at $2.03M in Q3 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Russell Investments Group held 14,230 shares of Coherus Oncology worth $24K as of Q1 2026.
  • Russell Investments Group bought 5,446 Coherus Oncology shares in Q1 2026, an estimated $9.67K.
  • Coherus Oncology made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3567 holding.
  • Russell Investments Group first reported a position in Coherus Oncology in Q4 2016 and has held it in 22 quarters since.
  • Russell Investments Group's Coherus Oncology position peaked at $2.03M in Q3 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.